Alabama Drug Discovery alliance

advertisement
AN
ALABAMA DRUG DISCOVERY ALLIANCE
LECTURE
BROUGHT TO YOU BY:
THURSDAY, OCTOBER 13, 3:00 PM
WEST PAVILION, ROOM E
THOMAS D.Y. CHUNG, PHD
DIRECTOR OF OUTREACH & PROJECT MANAGER
CONRAD PREBYS CENTER FOR CHEMICAL GENOMICS
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
LA JOLLA, CA
HOW THE CPCCG & THE NIH MLPCN*
CAN HELP YOU IN
TRANSLATIONAL SCIENCE
*Molecular Libraries Probe Production Centers Network
For more
information:
adda@uab.edu
Light refreshments will be served
High-Throughput Screening and Drug
Discovery at the Sanford-Burnham
Medical Research Institute
“T.C.” Chung, Ph.D., Director of Outreach & Project Manager, NIH MLPCN of the Conrad Prebys
Center for Chemical Genomics (CPCCG) at the Sanford-Burnham Medical Research Institute will
visit Southern Research Institute and the University of Alabama at Birmingham on Thursday,
October 13, 2011. Dr. Chung will present a seminar entitled “How the CPCCG & the NIH MLPCN
network can help you in translational science” in which he will describe the impressive worldclass capabilities, infrastructure, scientific staff (+500 person-yrs pharma & biotech experience),
compound collections (over 850,000 samples) and accomplishments (~99 HTS & 19.6MM
datapoints) of the bio-coastal (San Diego, CA and Orlando, FL) operations for automated highthroughput screening (~40 HTS/yr) and lead discovery.
Briefly, CPCCG can develop, implement, and execute virtually any biochemical, cell-based
(including phenotypic, pathway and High Content Screening) automated high-throughput assays
(>1 datapoints/day). CPCCG automated systems also support rapid medium to high-throughput
full dose response titrations, to support medicinal chemistry and chemical informatics
departments with proven expertise and experience in hit-to-probe optimization through SAR
development, directed chemical synthesis of analogs, along with full bio-analytical, biophysical
(NMR, microITC, ASMS), chem/bio-informatics, structure-based drug design, computational
chemistry, ADME/T capabilities and exploratory pharmacology to support up to small animal
PK/PD dosing.
CPCCG uHTS Robotic Screening System
High-Throughput Screening and Drug
Discovery at the Sanford-Burnham
Medical Research Institute – cont.
CPCCG is one of four Comprehensive Screening Centers of the nine centers of the Molecular
Libraries Probe Production Centers Network (MLPCN), the production phase of the NIH’s 6-yr
Molecular Libraries Program (MLP) that began on September 2, 2008. CPCCG is also one of five
Comprehensive Screening Centers of the twelve centers of the NCI Chemical Biology Consortium
(CBC). The MLP focuses on chemical biology and probe discovery. It solicits Investigator initiated
high-thoughput assays proposal for peer-reviewed competitive funding. Awarded proposals are
assigned to collaborate with one of the MLPCN centers for HTS execution on the > 350,000
compounds of the Molecular Libraries Small Molecule Repository (MLSMR) to eventual probe
development and publication. The complementary CBC focuses on drug discovery through to full
translational drug development through issuance of RFPs and Task Orders that centers and
Investigators can bid on. Through participation in these two networks, the CPCCG enables the
full portfolio of discovery and translational science to our collaborators. In particular, Dr. Chung
will outline the MLP grant programs and how the CPCCG could aid UAB and SRI faculty in the
application process highlighting the “outreach” support to investigators available to those
interested in applying for MLP grants and other grant and translational opportunities by
providing consultation, grant writing assistance, pre-grant access to CPCCG assay development
resources for preliminary data generation, and letters of support.
For more information about CPCCG capabilities, personnel, and MLPCN grant writing resources,
please visit their website: http://cpcc.sanfordburnham.org or contact:
MLPCN:
Thomas “T.C.” Chung, Ph.D.
Director Outreach
Project Manager, NIH MLPCN
858.795.5331
tchung@sanfordburnham.org
CBC:
“Chris” Hassig, Ph.D.
Director, Drug Development Services
Project Manager, NCI-CBC
858.795.5360
chassig@sanfordburnham.org
Download